Skip to content

Central Neuromodulation of Pain Through Music in Healthy Subjects

Central Neuromodulation of Pain Through Music in Healthy Subjects (DOUMU1)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03914105
Acronym
DOUMU1
Enrollment
24
Registered
2019-04-16
Start date
2019-10-15
Completion date
2020-02-25
Last updated
2021-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

The present research aims to study the neuromodulatory effect of music on the sensory component of pain. The activation of pain control systems, through music, would pave the way for rehabilitation prospects for patients with a deficit of these controls.

Detailed description

Pain is a multidimensional, complex and universal phenomenon that would be faced by almost one in two European adults. To meet the needs in terms of public health, contemporary medicine is gradually reintegrating the use of complementary therapeutic methods. Music therapy is a non-medical intervention that is particularly suited to pain problems. The therapeutic use of music is an economical, practical and safe method. Many clinical studies show that this activity promotes a significant decrease in pain. The ability of passive listening to music to reduce the perception of pain has been called music-induced analgesia. The neuro-psycho-physiological mechanisms that underlie this phenomenon remain poorly understood. One hypothesis, still discussed, proposes that listening to music would stimulate, directly or indirectly, endogenous mechanisms of modulation of pain, stemming from the brainstem. In individuals undergoing nociceptive tonic stimulation, the specific neuronal activation induced by listening to music demonstrates the involvement of inhibitory descending pathways. A measurement of pain control mechanisms would account for the impact of music on central awareness. The purpose of this research is therefore to study the neuromodulatory effect of music on the sensory component of pain. The activation of pain control systems, through music, would pave the way for rehabilitation prospects for patients with a deficit of these controls.

Interventions

PROCEDUREWithout music

The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration.

PROCEDUREWith music

The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration.

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects aged 18 to 65 * Subjects informed of the constraints of the study and having given their written consent. * Subjects benefiting from a social security scheme.

Exclusion criteria

* Subjects under 18 and over 65 * Subjects who have previously participated in a pain study involving the induced pain test. * Subjects with serious psychiatric disorders. * Subjects with a diagnosis of acute or chronic pain. * Subjects who have been taking antalgic substances for less than a week. * Subjects with progressive disease not stabilized by medical treatment. * Women in menstruation. * Pregnant women. * Subjects with a score greater than 10 for the Depressive Dimension on Hospital Anxiety and Depression Scale (HADS) * Subjects with an anxiety score state higher than anxiety traits on the Spielberger condition state / traits anxiety inventory (STAI) * Subjects with a score of 32 or higher on the Catastrophe Rating Scale (PCS-CF) * Non-cooperating person. * Person under legal protection * Subjects not benefiting from a social security scheme * Refusal of participation

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of Visual Analogue scale (VAS)20 minutesVisual Analogue Scale (VAS) measured at 2 minutes of stimulation during the temporal summation phase, starting from a basic VAS calibrated at 50/100. Pain is assessed continuously throughout this test using a computerized analog visual scale.

Secondary

MeasureTime frameDescription
Average VAS of the subject over the period P22 minutesThe period P2 represents the second stimulation or activation of the DNIC (Diffuse Nociceptive Inhibitive Control). This is the induction of cold thermal nociceptive stimulation (CPT : cold pressor test). The average VAS will be measured during this period. Pain is assessed continuously throughout this test using a computerized analog visual scale.
Average VAS of the subject over the period P32 minutesThe period P3 represents the third stimulation or the second time summation test. This is the second tonic pain test by applying the thermode.The average VAS will be measured during this period. Pain is assessed continuously throughout this test using a computerized analog visual scale.
Average VAS of the subject over the period P12 minutesThe period P1 represents the first stimulation or the first time summation test. It is a tonic pain test by applying the thermode. The average VAS will be measured during this period. Pain is assessed continuously throughout this test using a computerized analog visual scale.
Difference in average VAS P1-P320 minutesThe difference in average VAS between period P1 and period P3 will be calculated. Pain is assessed continuously throughout this test using a computerized analog visual scale.
Difference in Pressure Pain Threshold (PPT) before and after the procedure1 hour and 30 minutesThe difference in Pressure Pain Threshold (PPT) will be measured before and after the procedure.
Evaluation of numerical scale20 minutesNumerical scale (overall numerical scale over the period) will be measured for each stimulation period (P1, P2, P3). This scale assesses pain and is graded from 0 (no pain) to 100 (maximum pain imaginable).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026